Legend Biotech Corp ADR (LEGN) Implied Volatility Current

Tracking LEGN implied volatility helps you identify when options premiums on Legend Biotech Corp ADR are historically cheap or expensive, and where the best trades are hiding. Legend Biotech Corp ADR implied volatility reflects the market's expectation of future price movement: when LEGN IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Legend Biotech Corp ADR's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For LEGN, tracking metrics like LEGN IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on LEGN signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma.

In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where LEGN implied volatility sits today versus where it has been. Our scanner ranks Legend Biotech Corp ADR implied volatility against its historical range, surfaces extremes in LEGN IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Legend Biotech Corp ADR IV is rich or cheap — measure it, then act on it.